Copyright
©2010 Baishideng.
World J Gastroenterol. Mar 21, 2010; 16(11): 1414-1417
Published online Mar 21, 2010. doi: 10.3748/wjg.v16.i11.1414
Published online Mar 21, 2010. doi: 10.3748/wjg.v16.i11.1414
Report source | Sex/age (yr) | Liver disease/treatment | HCV genotype/serotype | Baseline/Lowest PLTs ( × 103/mL) | Duration of IFNαtreatment | Bleeding tendency | Antiplatelets antibodies/PAIgG | Mgk in bone marrow | Treatment | Outcome |
Shrestha et al[8] | M/41 | HCV/IFNα | NR | 6 | NR | Yes | Negative | Increased | NR | CR |
Dourakis et al[9] | M/39 | HCV/IFNα | NR | →/14 | 8 mo | Yes | NR | Increased | Steriods/IvIg | CR |
Dourakis et al[9] | F/64 | HCV/IFNα | NR | →/10 | 6 mo | Yes | Positive | Increased | Steriods/IvIg | CR |
Tappero et al[10] | F/NR | HCV/IFNα2a | NR | →/11 | 2 mo | NR | NR | NR | Steriods | CR |
Jiménez-Sáenz et al[11] | M/46 | HCV/IFNα2b | NR | →/3 | 3 yr | Yes | Positive | Increased | Steriods/IvIg | CR |
Pockros et al[12] | M/61 | HCV/IFNα | 1b | →/9 | 4 mo | Yes | Positive | NR | Steriods | CR |
Sagir et al[13] | M/45 | HCV/Peg-IFNα2b | NR | 147/9 | 10 wk | Yes | Negative | Increased | Steriods | CR |
Sevastianos et al[14] | F/38 | HCV, compensated cirrhosis/Peg-IFN2b | Group 4 | 141/5 | 4 wk | Yes | Positive | Increased | Steriods/IvIg | CR |
Fujii et al[15] | F/24 | HCV/IFNα | NR | →/1.1 | 4 wk | Yes | Positive | Increased | Steriods/IvIg | CR |
Dimitroulopoulos et al[16] | F/20 | HCV/IFNαcon-1 | 3a | →/11 | 28 wk | No | Positive | Increased | Steriods/IvIg | CR |
Medeiros et al[17] | M/40 | HCV/IFNα /PegIFNα2a | NR | →/6 | 6 mo | Yes | Positive | No performed | Steriods/IvIg | CR |
Nakajima et al[4] | M/47 | HCV/IFNα2a | 1b | 75/18 | 8 wk | Yes | Positive | Increased | IFN Discontinued | Not CR |
Lambotte et al[18] | F/73 | HCV/Peg-IFNα2a | 1b | 100/4 | 2 mo | Yes | Positive | Peripheral origin of the pancytopenia | Steriods/IvIg/PT | CR |
Demirtur et al[19] | F/40 | HCV/Peg-INF | NR | 217/6 | 13 wk | Yes | Positive | Increased | Danazol/IvIg | CR |
Elefsiniotis et al[20] | M/27 | HCV/Peg-IFNα2b | NR | 150/10 | 48 wk (6 mo after IFN discontinued) | Yes | Positive | Increased | Steriods | CR |
Alves Couto et al[21] | M/44 | HCV/Peg-IFNα2b | Group 3 | 164/2 | 16 wk | No | Negative | Increased | Steriods | CR |
Our hospital | F/54 | HCV/Peg-IFNα2a | 1b | 100/1 | 3 mo | Yes | Positive | Increased | Steriods/IvIg/PT | CR |
- Citation: Li L, Han DK, Lu J. Interferon-α induced severe thrombocytopenia: A case report and review of the literature. World J Gastroenterol 2010; 16(11): 1414-1417
- URL: https://www.wjgnet.com/1007-9327/full/v16/i11/1414.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i11.1414